Tizanidine Tablet
Product Images NDC 55154-7287

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 55154-7287). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
The text describes a figure showing the mean concentration of tizanidine over time for tablets and capsules of a 2 x 4 mg dose, under both fasted and fed conditions.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
The text describes a figure numbered as 2, that presents a study about the change in muscle tone of a single dose, where the measurement was made using the Ashworth Scale. The results are shown in negative figures that mean an improvement in muscle tortefrom when compared to the baseline. The confidence interval was of 95% and the time measured was in hours post-dose.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
FDA Label Image

Bag Label (Image 01)

Bag Label (Image 01)
Tizanidine Tablets, USP 4 mg is a medication for which each tablet contains 4.576 mg tizanidine hydrochloride equivalent to 4 mg tizanidine base. The usual dosage and complete prescribing information, precautions, and warnings can be obtained from the product insert found on the website majorpharmaceuticals.com. The tablets should be stored at 20° to 25° C (88° to 77° F), with excursions permitted from 15° to 30° C (59° to 86° F). This product is not interchangeable with tizanidine capsules or Zanaflex capsules. It is available in a unit dose package that is not child-resistant and is intended for institutional use only. The drug should be kept out of the reach of children and dispensed in a tight, light-resistant container. Zanaflex is a registered trademark of Accorda Therapeutics Inc. The tablets are manufactured by Apotex Inc, Toronto, Ontario, Canada, and distributed by Major Pharmaceuticals, Livonia, MI, USA, and Cardinal Health, Dublin, OH, USA.*
FDA Label Image

Chemical-structure (Tizanidine Imtb 01)

Chemical-structure (Tizanidine Imtb 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.